Elite in Hepatitis C

Dr. Elizabeth Verna

Hepatology
Trustees Of Columbia University In The City Of New York
1150 Saint Nicholas Ave, 
New York, NY 
Offers Telehealth
Elite in Hepatitis C
Trustees Of Columbia University In The City Of New York
1150 Saint Nicholas Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Verna is a Hepatologist in New York, New York. Dr. Verna is rated as an Elite provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis, Hepatitis C, Liver Failure, Liver Transplant, and Colonoscopy.

Her clinical research consists of co-authoring 237 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 40 articles and participated in 6 clinical trials in the study of Hepatitis C.

Specialties
Hepatology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
1150 Saint Nicholas Ave, New York, NY 10032

Additional Areas of Focus

Dr. Verna has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Epclusa
Study Phase: Phase 2
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
Per-Oral Cholangioscopy in Liver Transplantation Patients
Per-Oral Cholangioscopy in Liver Transplantation Patients
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Device
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Enrollment Status: Completed
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 12 Less Clinical Trials

237 Total Publications

Embracing Imperfect Tools to Decode AKI in Decompensated Cirrhosis.
Embracing Imperfect Tools to Decode AKI in Decompensated Cirrhosis.
Journal: Digestive diseases and sciences
Published: August 25, 2025
Similar Doctors
Douglas Dieterich
Elite in Hepatitis C
Dr. Douglas Dieterich
Hepatology
Elite in Hepatitis C
Dr. Douglas Dieterich
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Fl 12, 
New York, NY 
 (3.6 miles away)
212-659-8086
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Dieterich is a Hepatologist in New York, New York. Dr. Dieterich is rated as an Elite provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Elite in Hepatitis C
Dr. Ira Jacobson
Hepatology
Elite in Hepatitis C
Dr. Ira Jacobson
Hepatology

New York University

530 1st Ave, 
New York, NY 
 (7.1 miles away)
212-263-7300
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Hepatologist in New York, New York. Dr. Jacobson has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Liver Transplant, and Endoscopy.

Elite in Hepatitis C
Dr. Thomas Schiano
Hepatology
Elite in Hepatitis C
Dr. Thomas Schiano
Hepatology

Icahn School Of Medicine At Mount Sinai

579 Franklin Tpke, 
Ridgewood, NJ 
 (13.2 miles away)
201-251-3485
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Schiano is a Hepatologist in Ridgewood, New Jersey. Dr. Schiano is rated as an Elite provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Verna's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile